rheumatoid arthritis market size Overview by revenue and forecast to 2022
Global Rheumatoid arthritis market Information, by drug type (Nonsteroidal anti-inflammatory drug type (NSAID), Steroids, Biologic agents) by diagnosis (C-Reactive Protein (CRP) Test, CCP, ESR test) by treatment (Synovectomy, Tendon repair, Joint fusion) - Forecast to 2022
Global Rheumatoid Arthritis Market - Overview
Rheumatoid arthritis is a chronic inflammatory condition that possible can distress more than just the joints. It is found that in some individuals, the disorder also can damage a various parts of body system, including the lungs, skin, eyes, heart and blood vessels. The global rheumatoid arthritis market is expected to grow at a healthy CAGR of ~4% during the forecast period 2017-2022.
According to the report published by rheumatoid arthritis market size Research Future (MRFR), the global rheumatoid arthritis market can expect robust growth during the forecast period (2016-2022). Rheumatoid arthritis is an autoimmune disorder that makes joints its primary targets. The joints get swollen, warm, and the disease makes it painful. The probability of joints from both sides getting affected is alarmingly high, like if the wrist gets affected on the left first, then a chance of the right becoming prone to the disease is relatively higher.
Competitive Landscape:
These companies use strategies like merger, acquisition, marketing, branding, innovation, and other methods to stay abreast in the competitive market. Several companies like Pfizer Inc (U.S), AstraZeneca (U.K), Eli Lilly and company (U.S), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Company (U.S), Novartis AG (Switzerland), Vertex Pharmaceuticals Incorporated (U.S), Sanofi (France), and others are expected to make notable contributions.
Global Rheumatoid Arthritis Market - Regional Analysis
The global market is segmented into the various regions including Americas, Europe, Asia Pacific, and the Middle East & Africa. The Americas accounts for the largest market share of about more than ~38 market share due to increasing patient pool visiting professionals due to rheumatoid arthritis and favourable governmental conditions for research and development. According to the study conducted by the Centers for Disease Control and Prevention in March 2017 it was estimated that about 54.4 million U.S. adults suffer from arthritis that is approximately about 25% of its population. Arthritis is the key cause of disability, and causing pain, aching, stiffness, and swelling of the joints. The most common type of arthritis is rheumatoid arthritis & osteoarthritis. According to the same study it is expected that by 2040, 78 million i.e. 26% of the U.S. adults of age 18 years or older are anticipated to have doctor-diagnosed arthritis.
Get full Report @ https://www.marketresearchfuture.com/reports/rheumatoid-arthritis-market-1658
Intended Audience
- Pharmaceutical companies
- Rheumatoid arthritis treatment centers
- Contract Research Organizations (CROs)
- Research and Development (R&D) Companies
- Government Research Laboratories
- Independent Research Laboratories
- Government and Independent Regulatory Authorities
- Market Research and Consulting Service Providers
- Medical Research Laboratories
- Academic Medical Institutes and Universities
More Healthcare Related Reports
About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact:
